Results 111 to 120 of about 349,757 (388)

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

4P Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing [PDF]

, 2023
E. Lin, Y-C. Lo, Keertan Amit Parikh, N.K. Smrecek, K. Goliwas, J. Deshane, B. El-Rayes, Aakash Desai   +7 more
openalex   +1 more source

Human Vault Nanoparticle Targeted Delivery of Antiretroviral Drugs to Inhibit Human Immunodeficiency Virus Type 1 Infection. [PDF]

, 2019
"Vaults" are ubiquitously expressed endogenous ribonucleoprotein nanoparticles with potential utility for targeted drug delivery. Here, we show that recombinant human vault nanoparticles are readily engulfed by certain key human peripheral blood ...
Anton, Peter A, Deming, Timothy, Elliott, Julie, Fulcher, Jennifer A, Ibarrondo, F Javier, Kickhoefer, Valerie A, Maynard, Heather D, Mrazek, Jan, Rome, Leonard H, Tamshen, Kyle, Wollenberg, Alexander L, Yang, Otto O   +11 more
core  

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Will antibody-drug conjugate and immune checkpoint inhibitor-based combination therapy close the gap between benefit and toxicity in the treatment of cancers? A systematic review and meta-analysis [PDF]

, 2023
Leyin Zhang, Yici Yan, Yixin Chen, Jiamin Lu, Binbin Wang, Ning Ren, Leitao Sun   +6 more
openalex   +1 more source

The effects of zinc sulfate on ethyl glucuronide immunoassay urine testing [PDF]

, 2016
Published research in the Journal of Analytical Toxicology and the American Society for Clinical Pathology has confirmed that the presence of Zinc Sulfate in adulterated urine samples can influence the testing results using EMIT and ELISA immunoassay ...
Cawley, Shanna Marie
core   +1 more source

Laboratory evaluation of a rapid IgG4 antibody test (BLF Rapid™) for bancroftian filariasis [PDF]

, 2018
At the end phase of the Global Programme to Eliminate Lymphatic Filariasis, antibody testing may have a role in decision-making for bancroftian filariasis–endemic areas.
Babu, Subash, Fischer, Peter U, Hisam, Shamilah, Mahmud, Rohela, Noordin, Rahmah, Robinson, Keri, Won, Kimberly Y, Yunus, Muhammad H   +7 more
core   +2 more sources

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

Cancer, 2019
Glembatumumab vedotin is an antibody‐drug conjugate that produced preliminary clinical activity against advanced melanoma in a phase 1 dose‐escalation trial.
P. Ott, A. Pavlick, Douglas B. Johnson, L. Hart, J. Infante, J. Luke, J. Lutzky, N. E. Rothschild, L. Spitler, C. Cowey, A. Alizadeh, A. Salama, Yi He, T. Hawthorne, R. Bagley, Joshua Zhang, C. Turner, O. Hamid   +17 more
semanticscholar   +1 more source

First-line therapy in HER2 positive metastatic breast cancer. Is the mosaic fully completed or are we missing additional pieces? [PDF]

, 2016
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for women with early-stage and advanced ...
Cognetti F., Fabi A., Malaguti P., Vari S.   +3 more
core   +2 more sources